Jun 21 |
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
|
Jun 21 |
Palatin initiates Bremelanotide-PDE5i Phase II trial for ED
|
Jun 20 |
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
|
Jun 13 |
Palatin Technologies commences Phase II study of obesity treatment
|
Jun 12 |
Palatin starts Phase 2 obesity study of bremelanotide with Zepbound
|
Jun 12 |
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
|
May 20 |
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
|
May 16 |
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
|
May 16 |
Q3 2024 Palatin Technologies Inc Earnings Call
|
May 15 |
Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript
|